Marie-anne A. Hospital

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Journal: Blood advances

Published: May 13, 2026

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Journal: British journal of haematology

Published: March 05, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Psychosocial needs in oncology: From observation to action, a major challenge for adolescents and young adults

Psychosocial needs in oncology: From observation to action, a major challenge for adolescents and young adults

Journal: Bulletin du cancer

Published: October 31, 2025

Intermediate-Dose Cytarabine as Postinduction AML Therapy.

Intermediate-Dose Cytarabine as Postinduction AML Therapy.

Journal: NEJM evidence

Published: June 24, 2025

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Journal: Blood cancer journal

Published: May 04, 2025

Pronostic factors for survival in candidemia among onco-hematology patients: a single-center retrospective study during 10 years.

Pronostic factors for survival in candidemia among onco-hematology patients: a single-center retrospective study during 10 years.

Journal: Journal de mycologie medicale

Published: March 28, 2025

Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1.

Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1.

Journal: British journal of haematology

Published: December 21, 2024

Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.

Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.

Journal: European journal of haematology

Published: October 27, 2024

Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.

Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.

Journal: American journal of hematology

Published: October 20, 2024

CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.

CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.

Journal: Frontiers in immunology

Published: August 28, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026